Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
about
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapyProteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2.Plasma proteome changes associated with refractory cytopenia with multilineage dysplasiaParticulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsSPR imaging biosensor for the 20S proteasome: sensor development and application to measurement of proteasomes in human blood plasma.Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenancePlasma proteasomal chymotrypsin-like activity correlates with prostate cancer progression.Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease.Proteasome and C-reactive protein inflammatory response in children undergoing shorter and longer lasting laparoscopic cholecystectomy.Effective targeting of primitive AML CD34+ cells by the second-generation proteasome inhibitor carfilzomib.Essential amino acid mixtures drive cancer cells to apoptosis through proteasome inhibition and autophagy activation.Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer.Circulating proteasomes: circling myeloma with a new potential biomarker.
P2860
Q28534042-C4DE65A3-6E6F-420A-B05A-BCA1A65BE5A5Q33748408-A0FEFF39-E1E2-4E5F-8894-EDD7B8095652Q35338994-FF6E493C-CE04-4072-AEC2-129B4B067DEFQ35759402-507C8346-33C6-4532-84F6-2F8A8D45F43CQ35836881-3C3EA845-0D4A-4DB2-A0C7-FCCC2F9E5F1EQ36125132-D87012CB-C364-4976-8BE5-D25AC58D488CQ37017342-A8832869-C5EC-4034-8975-A054325C1078Q38559057-73C18484-C7DE-481B-A940-84B4F76904DFQ38813967-13B4B4E7-AC26-4CAB-9B9D-DB8C5222841DQ38921156-20C91B4A-6AC2-4D64-A1E4-793A739B80BEQ39336938-D3C21016-6B08-4FFD-BD7C-BFFA32142B45Q40521248-1727FC2E-3C82-4516-8CA5-5C4152062891Q46056334-1E693179-FC12-4AE2-B26A-8655AEFF9D6CQ47664209-4027A881-C259-4A8C-8002-258944FB47C3Q50280560-1D678868-CDAD-4E25-9343-7D62B9CFE2B8Q50660795-ACA78A87-E3AA-4692-954B-6E2E30881524Q52351127-145BF76A-0EEE-4623-ADA6-335A092D60B7Q52751890-A697D5B5-C0BE-483D-A7E6-EFAACFD928D5
P2860
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Proteasome enzymatic activitie ...... tage myelodysplastic syndrome.
@ast
Proteasome enzymatic activitie ...... tage myelodysplastic syndrome.
@en
type
label
Proteasome enzymatic activitie ...... tage myelodysplastic syndrome.
@ast
Proteasome enzymatic activitie ...... tage myelodysplastic syndrome.
@en
prefLabel
Proteasome enzymatic activitie ...... tage myelodysplastic syndrome.
@ast
Proteasome enzymatic activitie ...... tage myelodysplastic syndrome.
@en
P2093
P2860
P50
P1476
Proteasome enzymatic activitie ...... tage myelodysplastic syndrome.
@en
P2093
Amber C Donahue
Benjamin Bekele
Elihu Estey
Wanlong Ma
Zhong J Zhang
P2860
P304
P356
10.1158/1078-0432.CCR-08-3034
P407
P50
P577
2009-05-19T00:00:00Z